<Research>CICC Ratings, TPs on Medical Health Stocks (Table)

Written by Emily J. Thompson, Senior Investment Analyst

Source: aastocks

Updated: Aug 13 2025

0mins

00512-0.5%

01093-0.82%

01177+0.78%

Should l Buy 00512?

Source: aastocks

Stock Performance Overview: Several pharmaceutical stocks in Hong Kong, including SKB BIO-B and INNOVENT BIO, showed positive gains with notable short selling ratios, indicating varying investor sentiments and market dynamics.
Market Insights: Analysts maintain an "Outperform" rating on multiple companies like HENGRUI PHARMA and CSPC PHARMA, highlighting strong fundamentals despite some stocks experiencing price weakness.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy 00512?" and start using high-conviction signals backed by rigorous historical data.

00512

$7.89+Infinity%1D

Analyst Views on 00512

Wall Street analysts forecast 00512 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00512 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Analyst Rating

0 Buy

0 Hold

0 Sell

Current: 7.930

Low

Averages

High

Current: 7.930

Low

Averages

High

No data

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GRAND PHARMA Obtains Exclusive Rights to Market Allergy Medication Neffy in China

Dec 23 2025aastocks

Product Cooperation Agreement: GRAND PHARMA has entered into a product cooperation agreement with Pediatrix Therapeutics for the adrenaline nasal spray, Neffy.
Commercialization Rights: The Group will acquire exclusive commercialization rights in Mainland China and non-exclusive rights in Hong Kong for Neffy.
Localized Production Plans: GRAND PHARMA plans to achieve localized production of Neffy within 24 months after receiving product approval.
Short Selling Information: The company has reported short selling of $3.75 million with a ratio of 26.016%.

<Research>CICC Expects Commercial Insurance Innovative Drug Catalog Adjustments to Help High-Value Innovative Drugs Land

Aug 13 2025aastocks

Drug Catalog Adjustments: China's NHSA has announced the preliminary review of adjustments to drug catalogs for basic medical insurance, maternity insurance, work injury insurance, and commercial insurance, with 534 drugs passing the review. A dual catalog mechanism is expected to be implemented to differentiate between essential clinical drugs and high-value innovative drugs.
Investment Opportunities: CICC predicts that the expansion of commercial insurance will encourage investment in innovative drug R&D, benefiting companies like BEIGENE and others listed, as they focus on high-value drugs not covered by standard medical insurance.